Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Debt Ratio (2016 - 2025)

ImmunityBio (IBRX) has disclosed Debt Ratio for 12 consecutive years, with 0.61 as the latest value for Q3 2025.

  • On a quarterly basis, Debt Ratio rose 99.82% to 0.61 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.61, a 99.82% increase, with the full-year FY2024 number at 0.74, up 141.07% from a year prior.
  • Debt Ratio was 0.61 for Q3 2025 at ImmunityBio, down from 0.76 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 1.5 in Q1 2021 to a low of 0.27 in Q1 2024.
  • A 5-year average of 0.78 and a median of 0.75 in 2024 define the central range for Debt Ratio.
  • Peak YoY movement for Debt Ratio: soared 22305.32% in 2021, then crashed 72.54% in 2024.
  • ImmunityBio's Debt Ratio stood at 1.29 in 2021, then plummeted by 36.64% to 0.82 in 2022, then tumbled by 62.21% to 0.31 in 2023, then surged by 141.07% to 0.74 in 2024, then fell by 17.98% to 0.61 in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Debt Ratio are 0.61 (Q3 2025), 0.76 (Q2 2025), and 0.98 (Q1 2025).